Crystal Structure, Solubility, and Pharmacokinetic Study on a Hesperetin Cocrystal with Piperine as Coformer

Yanjie Liu, Fan Yang, Xiuhua Zhao, Siying Wang, Qilei Yang, Xiaoxue ZhangPharmaceutics 2022 · DOI

TL;DR

Researchers have successfully created a novel cocrystal of hesperetin (HES) and piperine (PIP) to improve HES's poor water solubility and bioavailability. This HES-PIP cocrystal exhibits enhanced solubility and a six-fold increase in oral bioavailability compared to pure HES, offering a promising avenue for developing more effective oral formulations of HES.

What Problem Does This Paper Address?

Hesperetin (HES), a natural flavonoid found in citrus peels, possesses a wide range of beneficial bioactivities, including antioxidant, anti-inflammatory, and anti-diabetic properties. However, its clinical development and therapeutic application are significantly hindered by its poor water solubility, which limits its absorption and bioavailability when taken orally. To overcome this challenge, the researchers explored the concept of cocrystallization, a technique that involves forming a crystalline structure with a second molecule (a coformer) to modify the physicochemical properties of the active pharmaceutical ingredient. They specifically chose piperine (PIP) as the coformer, recognizing its known role as a "bioenhancer" that can improve the absorption of poorly soluble drugs. The problem, therefore, is to develop a stable, cocrystalline form of HES with PIP that demonstrably improves its solubility and bioavailability.

Methods

The study employed a multi-faceted approach to characterize the HES-PIP cocrystal:

  • Cocrystal Preparation: Solution crystallization was used to synthesize the HES-PIP cocrystal. Different molar ratios of HES and PIP were dissolved in ethanol, mixed, and then allowed to crystallize.
  • Single-Crystal X-ray Diffraction (SCXRD): This was the primary technique used to determine the precise three-dimensional structure of the cocrystal, revealing the arrangement of HES and PIP molecules and the nature of the interactions between them.
  • Powder X-Ray Diffraction (PXRD): Used to confirm the crystalline phase purity of the synthesized cocrystal and compare it with the simulated PXRD pattern derived from SCXRD data. It also helped in analyzing the solid residue after solubility tests.
  • Differential Scanning Calorimetry (DSC) and Thermogravimetric Analysis (TGA): These thermal analysis techniques were used to investigate the thermal behavior of HES, PIP, and their cocrystal, helping to identify melting points and assess the presence of any solvates or hydrates. DSC was also used for preliminary screening of cocrystal formation.
  • Fourier Transform Infrared (FTIR) Spectroscopy: Employed to identify intermolecular interactions, particularly hydrogen bonding, within the cocrystal by analyzing shifts in characteristic vibrational frequencies of functional groups.
  • Solubility Experiments: The solubility of the HES-PIP cocrystal was measured in simulated gastrointestinal fluids at different pH values over time. This was compared to the solubility of pure HES and a physical mixture of HES and PIP.
  • High-Performance Liquid Chromatography (HPLC): Used for quantitative analysis in solubility studies and for determining drug concentrations in plasma during pharmacokinetic studies.
  • Bioavailability Study: A pharmacokinetic study was conducted in Sprague-Dawley rats to compare the plasma drug concentration-time profiles of pure HES, a physical mixture of HES and PIP, and the HES-PIP cocrystal. This allowed for the calculation of key pharmacokinetic parameters, including Cmax, AUC, and bioavailability.

Datasets

Not discussed in the paper. The study relies on experimental data generated from the synthesized materials and in vivo animal studies.

Key Insights and Ideas

  • Successful Cocrystal Formation: The study successfully demonstrated the formation of a stable 1:1 cocrystal between HES and PIP, overcoming HES's inherent solubility limitations.
  • Hydrogen Bonding as the Key Interaction: SCXRD revealed that the cocrystal is stabilized by specific O-H···O hydrogen bonds between the phenolic hydroxyl group of HES and the carbonyl and ether oxygen of PIP. This precise molecular interaction is crucial for the cocrystal's structure and properties.
  • The "Parachute Effect" in Action: The solubility studies showed an initial increase in HES concentration from the cocrystal, followed by a gradual decrease. This phenomenon, termed the "parachute effect," suggests that the cocrystal provides a supersaturated state for a sufficient period, allowing for enhanced absorption before it breaks down into its less soluble components.
  • Piperine's Dual Role: PIP not only acts as a coformer to improve HES's physical properties but also contributes as a bioenhancer. It likely inhibits drug efflux transporters (like P-glycoprotein) and metabolic enzymes (like CYP3A4), further increasing HES's systemic exposure.
  • Significant Bioavailability Improvement: The most striking finding is the six-fold increase in oral bioavailability of HES when formulated as a cocrystal with PIP, far exceeding the improvements seen with other HES cocrystals reported previously.

Key Results

  • Crystal Structure: The HES-PIP cocrystal crystallizes in the triclinic P-1 space group with a 1:1 stoichiometric ratio of HES to PIP. Key hydrogen bonds were identified between O1H1···O8 and O5H5···O7.
  • Solubility Enhancement: In simulated gastrointestinal fluid, the HES-PIP cocrystal achieved higher HES concentrations (44.89 µg/mL at pH 1.2 and 41.55 µg/mL at pH 6.8) compared to pure HES (23.13 µg/mL at pH 1.2 and 21.12 µg/mL at pH 6.8).
  • Supersaturation Factor (SF): While not explicitly quantified with a single number, the study indicates that the HES-PIP cocrystal leads to supersaturation, with AUC values for the cocrystal being higher than for a saturated HES solution.
  • Bioavailability Increase: The oral bioavailability of HES in the HES-PIP cocrystal was approximately six times higher than that of pure HES. The Cmax and AUC(0-t) for the cocrystal were 0.61 µg/mL and 3.23 µg/mL·h, respectively, compared to 0.12 µg/mL and 0.53 µg/mL·h for pure HES.

Limitations and Future Work

  • Limitations:
    • The study was conducted in animal models (rats), and further clinical trials would be necessary to confirm these findings in humans.
  • The "parachute effect" observed in solubility studies, while beneficial for absorption, implies that the cocrystal eventually breaks down. Understanding the long-term stability and dissolution profile in more complex biological environments could be important.
  • While PIP is generally considered safe, its potential for drug-drug interactions due to enzyme inhibition needs careful consideration in a clinical setting.
  • Future Work:
    • The authors suggest that this work provides an efficient oral formulation for HES and encourages further cocrystallization trials of PIP with other compounds to develop efficient oral formulations for drug combinations.
  • Further investigation into the long-term stability of the HES-PIP cocrystal under various storage conditions would be beneficial.
  • Exploring the mechanism of PIP's bioenhancement in more detail within the context of the HES-PIP cocrystal could lead to optimized formulations.

Summary updated

Abstract

Hesperetin (HES) is a key biological active ingredient in citrus peels, and is one of the natural flavonoids that attract the attention of researchers due to its numerous therapeutic bioactivities that have been identified in vitro. As a bioenhancer, piperine (PIP) can effectively improve the absorption of insoluble drugs in vivo. In the present study, a cocrystal of HES and PIP was successfully obtained through solution crystallization. The single-crystal structure was illustrated and comprehensive characterization of the cocrystal was conducted. The cocrystal was formed by two drug molecules at a molar ratio of 1:1, which contained O-H-O hydrogen bonds between the carbonyl and ether oxygen of PIP and the phenolic hydroxyl group of HES. In addition, a solubility experiment was performed on powder cocrystal in simulated gastrointestinal fluid, and the result revealed that the cocrystal improves the dissolution behavior of HES compared with that of the pure substance. Furthermore, HES's bioavailability in the cocrystal was six times higher than that of pristine drugs. These results may provide an efficient oral formulation for HES.
BibTeX
@inproceedings{liu2022crystal,
  author = {Yanjie Liu and Fan Yang and Xiuhua Zhao and Siying Wang and Qilei Yang and Xiaoxue Zhang},
  title = {{Crystal Structure, Solubility, and Pharmacokinetic Study on a Hesperetin Cocrystal with Piperine as Coformer}},
  booktitle = {Pharmaceutics},
  year = {2022},
  doi = {10.3390/pharmaceutics14010094},
}
Figure